{"drugs":["Amicar","Aminocaproic Acid"],"mono":{"0":{"id":"24828-s-0","title":"Generic Names","mono":"Aminocaproic Acid"},"1":{"id":"24828-s-1","title":"Dosing and Indications","sub":{"0":{"id":"24828-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Dental surgical procedure - Hemophilia - Hemorrhage; Treatment and Prophylaxis:<\/b> IV or ORAL, 75 mg\/kg (up to 6 g) immediately following surgery, then every 6 hr for 7-10 days<\/li><li><b>Dental surgical procedure - Hemophilia - Hemorrhage; Treatment and Prophylaxis:<\/b> Oral rinse, 5 mL (1.25 g) swished for 30 seconds 4 times a day for 7-10 days; small quantities may be swallowed (except when used during the first and second trimesters of pregnancy)<\/li><li><b>Hematuria, Surgical, non-surgical:<\/b> initial 4-5 gm IV, diluted in 250 mL of D5W or NS, infuse over 1 hr, followed by 1 g\/hr (50 mL\/hr) for about 8 hr or until bleeding is controlled<\/li><li><b>Hematuria, Surgical, non-surgical:<\/b> initial 5 g ORALLY during the first hr, followed by 1 g\/hr ORALLY for 8 hr or until bleeding is controlled<\/li><li><b>Hemorrhage - Increased fibrinolysis:<\/b> initial 4-5 gm IV, diluted in 250 mL of D5W or NS, infuse over 1 hr, followed by 1 g\/hr (50 mL\/hr) for about 8 hr or until bleeding is controlled<\/li><li><b>Hemorrhage - Increased fibrinolysis:<\/b> initial 5 g ORALLY during the first hr, followed by 1 g\/hr ORALLY for 8 hr or until bleeding is controlled<\/li><li><b>Subarachnoid hemorrhage, Recurrence:<\/b> IV or ORAL, 36 g\/day (18 g in 400 mL of D5W infused over each 12-hr period) for 10 days. Therapy is continued using orally administered aminocaproic acid<\/li><\/ul>"},"2":{"id":"24828-s-1-6","title":"Dose Adjustments","mono":"<b>renal impairment:<\/b> reduce dose to 15 to 25% of normal doses in patients with renal disease or oliguria"},"3":{"id":"24828-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Hematuria, Surgical, non-surgical<\/li><li>Hemorrhage - Increased fibrinolysis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Dental surgical procedure - Hemophilia - Hemorrhage; Treatment and Prophylaxis<\/li><li>Intraocular hemorrhage<\/li><li>Postoperative hemorrhage; Prophylaxis<\/li><li>Subarachnoid hemorrhage, Recurrence<\/li><\/ul>"}}},"3":{"id":"24828-s-3","title":"Contraindications\/Warnings","sub":[{"id":"24828-s-3-9","title":"Contraindications","mono":"disseminated intravascular coagulation <br\/>"},{"id":"24828-s-3-10","title":"Precautions","mono":"<ul><li>cerebral ischemia has occurred in patients treated for subarachnoid hemorrhage<\/li><li>cerebral vasospasm has occurred  in patients treated for subarachnoid hemorrhage<\/li><li>concomitant use with factor IX complex concentrates or anti-inhibitor coagulant concentrate should be avoided<\/li><li>hydrocephalus has occurred  in patients treated for subarachnoid hemorrhage<\/li><li>necrosis of heart and liver tissue has occurred in cases where skeletal myopathy is present<\/li><li>prolonged administration; risk of skeletal muscle weakness, necrosis of muscle fibers and rhabdomyolysis; monitoring recommended; discontinuation necessary<\/li><li>upper urinary tract bleeding; increased risk of intrarenal obstruction or glomerular capillary thrombosis; use alternative therapy in patients with hematuria of upper urinary tract origin or use with caution if the benefit of therapy outweighs the risk<\/li><\/ul>"},{"id":"24828-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"24828-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"24828-s-4","title":"Drug Interactions","sub":{"1":{"id":"24828-s-4-14","title":"Major","mono":"<ul><li>Anti-Inhibitor Coagulant Complex (theoretical)<\/li><li>Tretinoin (probable)<\/li><\/ul>"}}},"5":{"id":"24828-s-5","title":"Adverse Effects","mono":"<b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial necrosis<\/li><li><b>Hematologic:<\/b>Hemorrhage, Thrombosis<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Musculoskeletal:<\/b>Muscle necrosis, Proximal myopathy, Severe, Rhabdomyolysis<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident, Intracranial hypertension, acute, Seizure<\/li><li><b>Renal:<\/b>Myoglobinuria, Renal failure, Urinary tract obstruction<\/li><li><b>Respiratory:<\/b>Pulmonary embolism<\/li><\/ul>"},"6":{"id":"24828-s-6","title":"Drug Name Info","sub":{"0":{"id":"24828-s-6-17","title":"US Trade Names","mono":"Amicar<br\/>"},"2":{"id":"24828-s-6-19","title":"Class","mono":"Hemostatic<br\/>"},"3":{"id":"24828-s-6-20","title":"Regulatory Status","mono":"RX\/OTC<br\/>"},"4":{"id":"24828-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"24828-s-7","title":"Mechanism Of Action","mono":"Systemic: Aminocaproic acid competitively inhibits activation of plasminogen , thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots as well as fibrinogen and other plasma proteins including the procoagulant factors V and VIII . Aminocaproic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation .  In vitro, the antifibrinolytic potency of aminocaproic acid is approximately one-fifth to one-tenth that of tranexamic acid .<br\/>"},"8":{"id":"24828-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"24828-s-8-23","title":"Absorption","mono":"Systemic: Rapidly absorbed.<br\/>"},"3":{"id":"24828-s-8-26","title":"Excretion","mono":"Systemic: Renal <br\/>"},"4":{"id":"24828-s-8-27","title":"Elimination Half Life","mono":"Systemic: 2 h <br\/>"}}},"9":{"id":"24828-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>(infusion) dilute with NS, D5W, or LR; Sterile Water for Injection may also be used but will produce hypo-osmolar solution<\/li><li>rapid administration of undiluted injection into a vein is not recommended<\/li><\/ul>"},"10":{"id":"24828-s-10","title":"Monitoring","mono":"<ul><li>initial confirmed diagnosis of primary fibrinolysis prior to administration<\/li><li>CBC, DIC panel, and coagulation panel initially and after treatment<\/li><li>muscle enzymes, especially CPK with long term use; rhabdomyolysis, myositis, myalgia, muscle weakness<\/li><li>bradycardia, hypotension, peripheral ischemia, thrombosis<\/li><li>dyspnea, pulmonary embolism<\/li><li>BUN, renal failure<\/li><\/ul>"},"11":{"id":"24828-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Intravenous Solution: 250 MG\/ML<\/li><li>Oral Solution: 1.25 GM\/5 ML<\/li><li>Oral Tablet: 500 MG, 1000 MG<\/li><\/ul><\/li><li><b>Amicar<\/b><br\/>Oral Tablet: 500 MG<br\/><\/li><li><b>Novaplus Aminocaproic Acid<\/b><br\/>Intravenous Solution: 250 MG\/ML<br\/><\/li><\/ul>"},"13":{"id":"24828-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring coordination until drug effects are realized, as drug may cause dizziness.<\/li><li>This drug may cause nausea, vomiting, asthenia, headache, or drug-induced myopathy.<\/li><li>Tell patient to report bradyarrhythmia or hypotension.<\/li><li>Patient should report signs\/symptoms of rhabdomyolysis (myalgias, dark urine, arthralgias, fatigue), thrombotic disorder, peripheral ischemia, or renal failure.<\/li><li>Advise patient to call healthcare professional if a dose is missed, as drug should be given on a regular schedule.<\/li><\/ul>"}}}